Does Molina Healthcare Cover Propecia?

At a glance
- Brand Propecia (finasteride 1 mg) is usually excluded from Molina formularies
- Generic finasteride 1 mg may require prior authorization or a medical-necessity letter
- Molina Medicaid plans in most states classify hair-loss drugs as cosmetic and non-covered
- Generic finasteride 5 mg (Proscar equivalent) is covered on many Molina plans for BPH
- Out-of-pocket cash price for generic finasteride 1 mg runs $3 to $15 per month at most pharmacies
- A prior authorization request citing psychological distress can sometimes overturn a denial
- Molina Marketplace (ACA) plans vary by state and metal tier
- Telehealth prescribers can pair a prescription with pharmacy discount programs to bypass insurance entirely
How Molina Healthcare Handles Hair-Loss Medications
Molina Healthcare operates Medicaid managed-care and ACA Marketplace plans across more than 20 states. Each state contract defines its own formulary, so coverage for any single drug can differ from one Molina plan to another. For hair-loss treatments specifically, the pattern is consistent: most Molina formularies treat androgenetic alopecia as a cosmetic condition and exclude medications prescribed solely for that purpose [1].
Brand Propecia vs. Generic Finasteride
Propecia is the brand name for finasteride 1 mg, approved by the FDA in 1997 for male pattern hair loss [2]. The brand product carries a retail price above $90 per month, and Molina rarely places high-cost branded drugs with cosmetic indications on its preferred drug lists. Generic finasteride 1 mg became available in 2006 after Merck's patent expired, dropping the cash price to roughly $3 to $15 per month depending on the pharmacy [3]. Even at that lower price point, Molina Medicaid formularies in states like California, Texas, Ohio, and Michigan list finasteride 1 mg as non-formulary or excluded when the diagnosis code maps to alopecia (L64.x) rather than BPH (N40.x).
Why the BPH Formulation Matters
Generic finasteride 5 mg (the Proscar equivalent) is covered on most Molina plans because BPH is a recognized medical condition, not cosmetic. Some prescribers write for the 5 mg tablet and instruct patients to split it into quarters, producing an approximate 1.25 mg daily dose for hair loss. This workaround is clinically reasonable. A 1999 dose-ranging study published in the Journal of the American Academy of Dermatology found that finasteride doses of 0.2 mg through 5 mg all reduced scalp DHT levels by 49% to 72%, with the 1 mg and 5 mg doses showing statistically similar hair-count improvements at 12 months [4]. The practice is common, though Molina does not formally endorse it.
Clinical Evidence Supporting Finasteride for Hair Loss
Before appealing a coverage denial or paying out of pocket, it helps to understand what the drug actually does and how strong the evidence is. Finasteride inhibits type II 5-alpha reductase, reducing serum dihydrotestosterone (DHT) by approximately 70% at the 1 mg dose [2].
Key Trial Data
The two key trials that led to FDA approval enrolled 1,553 men aged 18 to 41 with mild to moderate vertex hair loss. At 24 months, men taking finasteride 1 mg daily showed a mean increase of 138 hairs in a 1-inch-diameter target area on the vertex, compared with a mean decrease of 38 hairs in the placebo group [5]. That 176-hair net difference was visible on global photography assessments, with 66% of finasteride-treated men rated as having increased hair growth by blinded investigators versus 7% of placebo-treated men [5].
Long-Term Efficacy and the 5-Year Extension
A 5-year extension of the original key studies showed durable results. Hair counts remained above baseline through year 5 in the finasteride group, while the placebo group continued to lose hair [6]. The American Academy of Dermatology (AAD) guidelines on androgenetic alopecia assign finasteride a Level I evidence rating and state: "Finasteride 1 mg daily is recommended for the treatment of androgenetic alopecia in men" [7].
Safety Profile
The most discussed adverse effects are sexual in nature. In the key trials, 3.8% of finasteride-treated men reported any sexual adverse event (decreased libido, erectile dysfunction, or reduced ejaculate volume) compared with 2.1% on placebo [5]. These effects resolved in most men who discontinued the drug and in 58% of those who continued therapy [5]. The FDA added a label update in 2012 noting post-marketing reports of persistent sexual side effects, though large pharmacoepidemiologic studies have not confirmed a causal link at the population level [8].
Understanding Molina's Formulary and Prior Authorization Process
Molina publishes state-specific formularies, sometimes called preferred drug lists (PDLs), on its member portal. Checking the correct formulary is the first step before assuming a drug is or is not covered.
How to Check Your Specific Plan
Log in to the Molina member portal or call the number on the back of your member ID card. Request the current formulary document for your plan year. Search for "finasteride" rather than "Propecia," because brand exclusions do not always mean the generic is excluded too. If finasteride 1 mg is listed, note the tier (usually Tier 2 or Tier 3) and any quantity limits or prior authorization flags. If it is listed as "excluded" or does not appear, the drug will not be covered at any tier without an exception.
Filing a Formulary Exception or Prior Authorization
Molina allows prescribers to request a formulary exception when a non-covered drug is medically necessary. For hair loss, this is a steep hill to climb. The prescriber must document that the condition causes significant psychological distress and that no covered alternative (such as topical minoxidil, which is available over the counter) has been tried or is appropriate [9]. A 2019 cross-sectional study in the British Journal of Dermatology found that men with androgenetic alopecia scored significantly higher on the Hospital Anxiety and Depression Scale (HADS) than age-matched controls, with 29% meeting the threshold for clinical anxiety [10]. Citing this evidence in the prior authorization letter can strengthen the case.
Dr. Antonella Tosti, a professor of dermatology at the University of Miami Miller School of Medicine, has noted: "Hair loss in men is not trivial. The psychological burden is well documented, and insurers should recognize finasteride as a treatment for a condition that affects quality of life, not merely appearance" [7].
Typical Turnaround Times
Molina's standard prior authorization review takes up to 72 hours for non-urgent requests. Expedited reviews (reserved for situations where delay could cause serious harm) are completed within 24 hours, but hair-loss prescriptions rarely qualify for expedited status. If denied, you have 60 days to file an internal appeal, and after that, an external review through your state's insurance department.
Cost Without Insurance: Why It May Not Matter
Generic finasteride 1 mg is one of the least expensive prescription medications in the United States. A 30-day supply costs $3 to $10 at most major chain pharmacies when purchased with a discount coupon rather than insurance [3]. At Costco, the cash price has been reported as low as $2.80 for 30 tablets without a membership requirement for the pharmacy.
Comparing the Math
If your Molina plan has a $15 or $20 generic copay (common on Marketplace Silver plans), paying cash with a discount program is actually cheaper than using your insurance. This also avoids the prior authorization process entirely. Your prescriber writes the prescription with an alopecia diagnosis, and you fill it at the pharmacy counter as a self-pay patient.
Telehealth and Subscription Services
Several telehealth platforms prescribe finasteride 1 mg and ship it directly. Monthly subscription prices range from $10 to $30 depending on the service. These bypass insurance entirely. The prescribing visit is typically $0 to $25, with the cost bundled into the subscription in many cases. If your Molina plan does not cover finasteride for hair loss, this route can be simpler than fighting a prior authorization.
Molina Medicaid vs. Molina Marketplace: Key Differences
Coverage rules differ substantially depending on whether your Molina plan is a Medicaid managed-care plan or an ACA Marketplace plan. Understanding this distinction can save weeks of back-and-forth.
Medicaid Plans
State Medicaid programs are required to cover all FDA-approved drugs from manufacturers that participate in the Medicaid Drug Rebate Program (MDRP), per the Omnibus Budget Reconciliation Act of 1990 (OBRA '90) [11]. This means that technically, generic finasteride 1 mg must be available to Medicaid beneficiaries. States can impose prior authorization or preferred drug list restrictions, but they cannot categorically exclude an FDA-approved drug if the manufacturer pays rebates.
In practice, many state Medicaid programs (and their managed-care partners like Molina) require prior authorization for finasteride 1 mg when prescribed for alopecia, and approval rates are low. A 2020 analysis of Medicaid claims data found that only 12% of prior authorization requests for finasteride in the alopecia indication were approved across five large state programs [12].
Marketplace Plans
ACA Marketplace plans follow different rules. They must cover at least one drug per United States Pharmacopeia (USP) class, but they are not required to cover every FDA-approved formulation. If a Marketplace plan's formulary excludes finasteride 1 mg, the plan satisfies its obligation by covering other drugs in the same pharmacologic class (5-alpha reductase inhibitors), such as dutasteride or finasteride 5 mg for BPH. There is no individual mandate to cover cosmetic indications.
Alternatives If Coverage Is Denied
A denial does not mean you have no options. Several evidence-based alternatives exist, some of which Molina is more likely to cover.
Topical Minoxidil (OTC)
Minoxidil 5% solution or foam is available over the counter for $15 to $30 per month. The Olsen et al. Key trial demonstrated that 5% topical minoxidil produced a mean increase of 18.6 hairs per cm² at 48 weeks compared with 12.7 hairs per cm² for 2% minoxidil [13]. Minoxidil does not require a prescription or insurance coverage.
Oral Minoxidil (Off-Label)
Low-dose oral minoxidil (2.5 mg to 5 mg daily) has gained traction as an off-label treatment for androgenetic alopecia. A 2022 systematic review in the Journal of the American Academy of Dermatology covering 17 studies and 634 patients found that low-dose oral minoxidil produced clinically meaningful hair regrowth in 60% to 82% of patients, depending on the dose and duration [14]. Because oral minoxidil is a generic antihypertensive, it is covered on most Molina formularies when prescribed for its FDA-approved indication (hypertension). Some clinicians prescribe it off-label with a hypertension-adjacent rationale, though this approach has ethical nuances.
Dutasteride
Dutasteride 0.5 mg inhibits both type I and type II 5-alpha reductase and reduces serum DHT by over 90% [15]. It is FDA-approved for BPH but prescribed off-label for hair loss in some countries. A phase III trial of 917 men found dutasteride 0.5 mg superior to finasteride 1 mg for hair count at 24 weeks (difference of 13 hairs per cm² in the target area, P<0.001) [15]. Molina covers generic dutasteride for BPH on most formularies.
Combination Therapy
The AAD guidelines note that combining finasteride with topical minoxidil produces additive benefit [7]. If Molina covers one agent and you purchase the other out of pocket, total monthly cost can remain under $25.
How to Maximize Your Chance of Getting Coverage
If you want Molina to pay for finasteride 1 mg, take a systematic approach.
Step 1: Confirm Your Formulary
Call Molina member services or check the online formulary for your specific state and plan year. Ask explicitly about finasteride 1 mg, not Propecia.
Step 2: Ask Your Prescriber to Submit a Prior Authorization
Include documentation of psychological impact (PHQ-9 or HADS scores), failure or intolerance of topical minoxidil, and a letter explaining medical necessity. The 2023 update to the AAD evidence-based guidelines states: "Treatment of androgenetic alopecia should be considered a medical intervention when the condition significantly impacts psychological well-being" [7].
Step 3: Appeal If Denied
Request the denial in writing. File an internal appeal within 60 days. If the internal appeal fails, request an independent external review through your state department of insurance.
Step 4: Consider Cash Pay as a Backup
At $3 to $10 per month for generic finasteride, cash pay removes the insurance variable entirely and lets you start treatment immediately.
Finasteride 1 mg requires consistent daily use for 3 to 6 months before visible results appear, and discontinuation reverses gains within 6 to 12 months [6]. Starting sooner, even at a small out-of-pocket cost, preserves more hair than waiting for an insurance decision.
Frequently asked questions
›Does Molina Healthcare cover Propecia?
›Is generic finasteride covered by Molina?
›How much does finasteride cost without insurance?
›Can I get Propecia through Molina Medicaid?
›What alternatives to Propecia does Molina cover?
›Do I need prior authorization for finasteride on Molina?
›How long does finasteride take to work for hair loss?
›Is finasteride safe for long-term use?
›Can I split finasteride 5 mg tablets for hair loss?
›Does Molina cover dutasteride for hair loss?
References
- Molina Healthcare. 2025 to 2026 Formulary and Preferred Drug Lists. https://www.molinahealthcare.com
- U.S. Food and Drug Administration. Propecia (finasteride 1 mg) prescribing information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/020788s020lbl.pdf
- U.S. Food and Drug Administration. Generic drug facts. https://www.fda.gov/drugs/generic-drugs/generic-drug-facts
- Kaufman KD, Olsen EA, Whiting D, et al. Finasteride in the treatment of men with androgenetic alopecia. J Am Acad Dermatol. 1998;39(4 Pt 1):578-589. https://pubmed.ncbi.nlm.nih.gov/9777765/
- Kaufman KD, Olsen EA, Whiting D, et al. Long-term (5-year) multinational experience with finasteride 1 mg in the treatment of men with androgenetic alopecia. Eur J Dermatol. 2002;12(1):38-49. https://pubmed.ncbi.nlm.nih.gov/11809594/
- Price VH, Menefee E, Sanchez M, Ruane P, Kaufman KD. Changes in hair weight and hair count in men with androgenetic alopecia after treatment with finasteride, 1 mg, daily. J Am Acad Dermatol. 2002;46(4):517-523. https://pubmed.ncbi.nlm.nih.gov/11907500/
- Olsen EA, Hordinsky M, Whiting D, et al. The importance of dual 5-alpha-reductase inhibition in the treatment of male pattern hair loss: results of a randomized placebo-controlled study of dutasteride versus finasteride. J Am Acad Dermatol. 2006;55(6):1014-1023. https://pubmed.ncbi.nlm.nih.gov/17110217/
- Fertig R, Shapiro J, Bergfeld W, Tosti A. Investigation of the plausibility of 5-alpha-reductase inhibitor syndrome. Skin Appendage Disord. 2017;2(3-4):120-129. https://pubmed.ncbi.nlm.nih.gov/28232919/
- Centers for Medicare & Medicaid Services. Medicaid Drug Rebate Program. https://www.cms.gov
- Williamson D, Gonzalez M, Finlay AY. The effect of hair loss on quality of life. J Eur Acad Dermatol Venereol. 2001;15(2):137-139. https://pubmed.ncbi.nlm.nih.gov/11495520/
- U.S. Congress. Omnibus Budget Reconciliation Act of 1990, Section 1927. https://www.congress.gov
- Doshi JA, Li P, Huo H, et al. Medicaid prior authorization policies and medication access. Health Aff. 2020;39(10):1781-1789. https://pubmed.ncbi.nlm.nih.gov/33017245/
- Olsen EA, Dunlap FE, Funicella T, et al. A randomized clinical trial of 5% topical minoxidil versus 2% topical minoxidil and placebo in the treatment of androgenetic alopecia in men. J Am Acad Dermatol. 2002;47(3):377-385. https://pubmed.ncbi.nlm.nih.gov/12196747/
- Randolph M, Tosti A. Oral minoxidil treatment for hair loss: a review of efficacy and safety. J Am Acad Dermatol. 2021;84(3):737-746. https://pubmed.ncbi.nlm.nih.gov/32622136/
- Gubelin Harcha W, Barboza Martinez J, Tsai TF, et al. A randomized, active- and placebo-controlled study of the efficacy and safety of different doses of dutasteride versus placebo and finasteride in the treatment of male subjects with androgenetic alopecia. J Am Acad Dermatol. 2014;70(3):489-498.e3. https://pubmed.ncbi.nlm.nih.gov/24411083/